Guerra Pan Advisors LLC Sells 32 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Guerra Pan Advisors LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,717 shares of the medical research company’s stock after selling 32 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.9% of Guerra Pan Advisors LLC’s portfolio, making the stock its 16th biggest holding. Guerra Pan Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,973,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $33,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at $36,000. Tyler Stone Wealth Management bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $37,000. DHJJ Financial Advisors Ltd. bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $38,000. Finally, Raleigh Capital Management Inc. raised its position in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TMO shares. Raymond James lifted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Royal Bank of Canada lifted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. HSBC began coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price for the company. Finally, Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $601.56.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $1.86 during mid-day trading on Tuesday, hitting $556.01. 386,112 shares of the stock were exchanged, compared to its average volume of 1,530,548. The company has a market cap of $212.23 billion, a PE ratio of 35.82, a price-to-earnings-growth ratio of 2.38 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The firm has a 50-day moving average of $571.79 and a two-hundred day moving average of $526.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm posted $5.40 EPS. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.